LongCOVID data tracks fatigue, symptoms by variant
Most research on SARS-CoV-2 variants focuses on initial symptomatology with limited data on longer-term sequelae. We sought to characterize the prevalence and differences in prolonged symptoms at three months post SARS-CoV-2-infection across the three major variant time-periods .
The study included 3,223 participants . Among the COVID-positive cohort, 463 were pre-Delta, 1,198 during Delta, and 741 during Omicron. Prolonged severe fatigue was highest in the pre-Delta COVID-positive cohort compared with Delta and Omicron cohorts , as was presence of ≥3 prolonged symptoms . No difference was seen in the COVID-negative cohort between variant time-periods. In multivariable models, there was no difference in severe fatigue between variants.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Many patients experience persistent pain after having Clade IIb mpoxIn a rapid communication published in the journal Eurosurveillance, researchers presented the interim results of a medium-term follow-up [three weeks to twenty weeks following MPOX virus infection follow-up study comprising patients attending sexual health clinics in Belgium.
Lire la suite »
Play park closed after 'severe' damage caused by 'vandals'A play park has been closed after it was allegedly damaged by vandals.
Lire la suite »
Prior COVID highly protective against severe disease ten months post-infectionIn a recent study published in the Lancet, researchers performed a systematic review of scientific literature published from inception up to September 31, 2022, that documented the reduction in risk of coronavirus disease 2019 (COVID-19) among individuals with a prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vis-à-vis those with no COVID-19 history.
Lire la suite »
Impact of continuous hypertonic (NaCl 20%) saline solution on renal outcomes after traumatic brain injury (TBI): a post hoc analysis of the COBI trial - Critical CareBackground To evaluate if the increase in chloride intake during a continuous infusion of 20% hypertonic saline solution (HSS) is associated with an increase in the incidence of acute kidney injury (AKI) compared to standard of care in traumatic brain injury patients. Methods In this post hoc analysis of the COBI trial, 370 patients admitted for a moderate-to-severe TBI in the 9 participating ICUs were enrolled. The intervention consisted in a continuous infusion of HSS to maintain a blood sodium level between 150 and 155 mmol/L for at least 48 h. Patients enrolled in the control arm were treated as recommended by the latest Brain Trauma foundation guidelines. The primary outcome of this study was the occurrence of AKI within 28 days after enrollment. AKI was defined by stages 2 or 3 according to KDIGO criteria. Results After exclusion of missing data, 322 patients were included in this post hoc analysis. The patients randomized in the intervention arm received a significantly higher amount of chloride during the first 4 days (intervention group: 97.3 ± 31.6 g vs. control group: 61.3 ± 38.1 g; p | 0.001) and had higher blood chloride levels at day 4 (117.9 ± 10.7 mmol/L vs. 111.6 ± 9 mmol/L, respectively, p | 0.001). The incidence of AKI was not statistically different between the intervention and the control group (24.5% vs. 28.9%, respectively; p = 0.45). Conclusions Despite a significant increase in chloride intake, a continuous infusion of HSS was not associated with AKI in moderate-to-severe TBI patients. Our study does not confirm the potentially detrimental effect of chloride load on kidney function in ICU patients. Trial registration: The COBI trial was registered on clinicaltrial.gov (Trial registration number: NCT03143751, date of registration: 8 May 2017).
Lire la suite »
After a previous BA.1 infection, Omicron BA.4/5 infection is more likely than BA.2In a recent study published in the journal Eurosurveillance, researchers investigated whether prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or coronavirus disease 2019 (COVID-19) vaccination protected against SARS-CoV-2 Omicron variant of concern (VOC) BA.4/5 sub-VOC or BA.2 sub-VOC infections.
Lire la suite »
How effective has the bivalent booster COVID vaccination been?In a recent study published in the journal Eurosurveillance, researchers estimated the effectiveness of bivalent messenger ribonucleic acid (mRNA) vaccines targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 subvariant and the original Wuhan-Hu1 strain against Omicron infections in the vaccinated population of the Netherlands between 26 September and 19 December 2022.
Lire la suite »